Biodegradable nanoparticle having T-cell recognizable epitope peptide immobilized thereon or encapsulated therein

A biodegradable nanoparticle technology, applied in the field of immunotherapy preparations, can solve the problems of low peptide permeability, no report on the use of biodegradable nanoparticles, and problems with oral administration

Inactive Publication Date: 2008-08-20
TAIHO PHARMA CO LTD +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] (2) Possibility of inducing increased production of IgG antibodies or inactivation of T cells by administering a large amount of peptides (Non-Patent Document 3)
[0014] (1) Due to the decomposition of enzymes, it cannot maintain a certain effective concentration (problem of stability)
[0015] (2) Due to the extremely low permeability of the digestive tract membrane to peptides, there are problems with oral administration
[0016] (3) Administered submucosally for the purpose of inducing a response by means of mucosal immunity, there is also a problem in tissue retention
[0021] As described above, there is no report on the use of biodegradable nanoparticles immobilized or encapsulating T cell-recognized epitope peptides as immunotherapeutic preparations for allergic diseases represented by asthma and hay fever.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biodegradable nanoparticle having T-cell recognizable epitope peptide immobilized thereon or encapsulated therein
  • Biodegradable nanoparticle having T-cell recognizable epitope peptide immobilized thereon or encapsulated therein
  • Biodegradable nanoparticle having T-cell recognizable epitope peptide immobilized thereon or encapsulated therein

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] (1) Production of PEGylated mouse fir pollen T cell recognition antigen epitope peptide

[0083] As the T cell recognition antigen epitope peptide of Cryj1 BALB / c mouse, select P1:277-290; KQVTIRIGCKTSSS (hereinafter referred to as P1), as the T cell recognition antigen epitope peptide of Cryj2 BALB / c mouse , select P2: 246-259; RAEVSYVHVNGAKF (hereinafter referred to as P2). The PEG (polyethylene glycol) synthesis of the peptide relies on Toray Research Center Co. Ltd., and synthesizes the PEG (polyethylene glycol)-recognized epitope peptide of mouse cedar pollen T cells through the Fmoc solid-phase synthesis method .

[0084] (2) Synthesis of biodegradable nanoparticles immobilized with mouse cedar pollen T cell recognition antigen epitope peptide

[0085] 607 mg (4.7 unit mmol) of poly(γ-glutamic acid) (γ-PGA, molecular weight 300,000) was dissolved in 100 ml of 54 mM aqueous sodium bicarbonate solution (pH 8.5). Then add 1-ethyl-3-(3-dimethylaminopropyl) carbodii...

Embodiment 2

[0087] Immunity-inducing ability of biodegradable nanoparticles immobilized with epitope peptides recognized by mouse fir pollen T cells

[0088] Biodegradable nanoparticles immobilized with Cryj1 or Cryj2 T cell-recognized epitope peptides (P1, P2) (equivalent to 20 μg of peptide) or 100 μl of suspension of nanoparticles without immobilized peptide (50 μl per foot). On the 11th day, the local lymph nodes were excised, and the lymph node cells were recovered and suspended in RPMI1640 medium + 10% fetal calf serum (FCS). In addition, pooled cells from two mice were used for each group. Cells were divided into 5×10 per well 5 Each was seeded in a 96-well plate, and then added P1 or P2 at a final concentration of 20 μg / ml as an antigen stimulation, or 10 μg / ml of cedar pollen crudely purified antigen (Sugi Basic Protein, SBP, Asahi Food and HealthCare Co., Ltd.) . 48 hours after the start of the culture, half the amount of the culture solution was mixed with [ 3 H] Fresh med...

Embodiment 3

[0092] Immunomodulatory effects of biodegradable nanoparticles immobilized with epitope peptides recognized by mouse fir pollen T cells

[0093] (1) Induction of Th1 cytokine immunity by subcutaneous administration

[0094] BALB / c mice (male, 10 weeks old) were subcutaneously injected with 100 μl of a suspension of biodegradable nanoparticles (equivalent to 50 μg of the peptide) of the Cryj1-immobilized T cell recognition epitope peptide (P1) on both paws ( 50 μl per foot). On the 16th day, 5 μg of crude purified antigen SBP from cedar pollen suspended in Freund's incomplete adjuvant was injected into the right paw to induce an immune response. On the 5th day after injection, local lymph node cells were recovered, seeded into 96-well plates by the same method as in Example 2, and then stimulated with crudely purified antigen SBP from cedar pollen at a final concentration of 10 μg / ml. Cell proliferation was measured using the method described in Example 2. For measurement of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A biodegradable nanoparticle having a T cell recognizable epitope peptide immobilized thereon or encapsulated therein of the present invention is usable as a safe and effective immunotherapeutic agent, and is useful as an immunotherapeutic agent for treating, for example, pollinosis, year-round nasal allergic disease and seasonal nasal allergic disease.

Description

technical field [0001] The present invention relates to biodegradable nanoparticles immobilizing or encapsulating T cell-recognized epitope peptides, especially T-cell-recognized antigen epitope peptides of pollen patients, and / or immunotherapy preparations using them. Background technique [0002] Immunotherapy for hay fever was discovered based on the injection of pollen extract in small amounts and incremental injections for hay fever patients in the 1910s. Later, the effectiveness of this method was confirmed and popularized empirically, and it is also called desensitization therapy. Compared with drug therapy, this immunotherapy is the only treatment that can be expected to cure, but on the other hand, because the antigen used is pollen extract (or its extract), side effects such as allergies may sometimes occur . Therefore, in order to suppress the occurrence of these side effects, only a very small amount can be administered, and there is a problem that the administ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K47/34A61K47/36A61K47/42A61K47/48A61P37/08
CPCA61K2039/57A61K47/48907A61K9/0048A61K39/35A61K9/5146B82Y5/00A61K9/0019A61K47/6935A61P11/02A61P37/08A61K39/00A61K47/34A61K47/42A61K47/50
Inventor 明石满生泽公一
Owner TAIHO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap